Teva and Samsung Bioepis Expand Partnership for Six New Biosimilars

Key Facts

Teva and Samsung Bioepis entered a global license and development agreement for up to six biosimilar candidates. Business Wire reported that the expanded strategic partnership focuses on the development and commercialization of these candidates, specifically naming SB41 and SB44.

The agreement aims to leverage Samsung Bioepis' development capabilities and Teva's commercialization network to bring more affordable biosimilar treatments to market. This expansion reflects a strategic move to strengthen the product pipeline within the pharmaceutical sector.